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Background: While reviews have been published on asthma management in pregnant women, none has examined
the effectiveness of non-pharmacological healthcare interventions for optimizing asthma management in pregnant
women. This systematic review aims to identify non-pharmacological healthcare interventions for optimizing asthma
management during pregnancy and to examine their effects on maternal asthma control and neonatal outcomes.
Methods: The Cochrane Central Register of Controlled Trials (CENTRAL, Cochrane Library), MEDLINE, EMBASE,
PsycINFO, CINAHL Plus and International Pharmaceutical Abstracts (IPA) were searched. Two reviewers independently
assessed the identified studies against the eligibility criteria and extracted relevant information. The effects of the
intervention were assessed qualitatively.
Results: Nine studies were identified, of which six were rejected according to the exclusion criteria. The three studies
included in the final review described an education program, progressive muscle relaxation (PMR) and Fraction of
exhaled Nitric Oxide (FeNO) guided management of asthma in pregnant women. The PMR and FeNO-guided
interventions showed significant improvements in maternal asthma control (lung function and quality of life) and
neonatal outcomes (birth weight).
Conclusions: Further evidence from well-designed studies evaluating non-pharmacological healthcare interventions
for optimizing asthma management in pregnant women is required.
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Asthma is one of the most serious health problems affect-
ing people of all ages throughout the world [1,2]. In the
United States of America the prevalence of self-reported
asthma among pregnant women was between 8.4% and
8.8% during the period 1997 to 2001, and 4.1% of all preg-
nant women had experienced an asthma attack in the pre-
vious year [3,4]. In Australia, asthma is the most common
chronic disease affecting pregnant women, complicating
one in eight pregnancies [5].* Correspondence: Johnson.George@monash.edu
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366 pregnancies in 330 women with asthma, showed
that during pregnancy, asthma improved in slightly more
than a quarter of patients (28%), worsened in slightly
more than a third of patients (35%) and remained un-
changed in a third of patients (33%). More than half of
women with asthma do not take their asthma preventer
medications on a regular basis before and during preg-
nancy, leading to asthma exacerbations [3,7]. Good asthma
control during pregnancy is important to reduce risks for
both mother (e. g. pre-eclampsia, perinatal mortality, and
need for cesarean delivery) and infant (e.g. low birth weight
and prematurity) [8,9]. Therefore, pregnant women with
asthma warrant additional support comprising education,
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guidelines for asthma management in pregnancy. They
include the British Thoracic Society, National Heart Lung
and Blood Institute (NHLBI), American College of Obste-
tricians & Gynecologists (ACOG) and the American
College of Asthma and Allergy (ACAAI), National Asthma
Council of Australia (NAC), and Global Initiative for
Asthma (GINA) [11-15]. All these guidelines have empha-
sized the need to provide optimal therapy to maintain
control of asthma throughout gestation for maternal
health and quality of life as well as for normal fetal matur-
ation. The Expert Panel Report of the Working Group
on Asthma and Pregnancy – Updates in National
Asthma Education and Prevention Program (NAEPP) –
has recommended four critical components for managing
asthma during pregnancy: (1) assessment and monitoring
of asthma including objective measures of pulmonary
function, (2) control of factors contributing to asthma se-
verity, (3) patient education, and (4) a stepwise approach
to pharmacological therapy [16]. Asthma management
during pregnancy requires close collaboration among ob-
stetricians, primary care physicians, and asthma-care spe-
cialists [17]. Better asthma control can be achieved if
patients are involved in self-management, including self-
monitoring of either symptoms or peak expiratory flow
rates, maintaining regular contact with medical practi-
tioners and following written asthma action plans [18].
While there are many published reviews of pharmaco-
logical asthma management in pregnant women [19,20],
none has assessed the effectiveness of non-pharmacological
healthcare interventions for optimizing asthma manage-
ment in pregnant women. Most of the interventions in
pregnant women have focused on the safety and efficacy
of asthma medications in pregnant women [21,22]. Gen-
eral practitioners (family physicians) have reported a lack
of confidence and/or knowledge in managing deteriorat-
ing asthma in pregnancy, although having a good under-
standing of the safety of asthma medications during
pregnancy [23]. Despite being concerned about health
outcomes, women are not well supported in managing
asthma during pregnancy [24]. Empirical evidence on in-
terventions to optimize asthma management during preg-
nancy, targeting both pregnant women with asthma and
their health professionals, is needed. The aim of this re-
view was to identify non-pharmacological healthcare in-
terventions for optimizing asthma management during
pregnancy and examine their effects on maternal asthma
symptoms and neonatal outcomes.
Methods
Eligibility criteria
To be included, studies had to describe the effectiveness
of non-pharmacological healthcare interventions for man-
aging asthma in pregnant women using one of the followingprospective study designs: randomized controlled trials
(RCTs) controlled clinical trials (CCTs), or pre- and post-
(uncontrolled before and after) studies. Studies of non-
pharmacological healthcare interventions in pregnant
women, including behavioral or educational interventions
targeting patients, patient self-management programs, pa-
tient monitoring and follow-up of asthma management
were eligible. Studies were excluded if they were not
aimed at pregnant women with asthma, comprised only
pharmacological interventions in the absence of interven-
tion by a healthcare professional (e. g. drug trials), or only
targeted healthcare professionals (e. g. education to im-
prove prescribing). Studies needed to have measured at
least one of the following primary or secondary outcomes
at baseline and at follow-up:
Primary outcomes for the review
1. Asthma symptom scores measured using any
validated instrument (e.g. Juniper’s Asthma Control
Questionnaire [ACQ] [25]).
2. Health-related Quality of Life (HRQoL) scores
measured using any validated instrument
(e.g. Asthma Quality of Life Questionnaire-Marks
[AQLQ-M] [26]).
3. Asthma -related scheduled or unscheduled healthcare
visits to emergency department (ED), general
practitioner (GP), or hospitalization.
Secondary outcomes
1. Lung function measurements (e.g. Peak expiratory
flow rate [PEFR], Forced expiratory volume
in one second [FEV1], Forced vital capacity
[FVC]).
2. Asthma medication adherence (assessed using a
valid instrument or objective data).
3. Neonatal outcomes (e.g. birth weight, survival,
Appearance, Pulse, Grimace, Activity, Respiration
(APGAR) scores, gestational age).
Information sources
A systematic search of the following databases was car-
ried out using the Cochrane Central Register of Controlled
Trials (CENTRAL, The Cochrane Library 2013), Ovid
MEDLINE, Ovid EMBASE, Ovid PsycINFO, CINAHL
Plus and International Pharmaceutical Abstracts (IPA). In
addition to searching these databases, reference lists from
previously published review articles were also searched.
The final search was carried out in October 2013.
Search strategies
Professional librarians were consulted in developing the
search strategy for each database. No language restrictions
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tion years. The broad terms asthma* AND pregnan*
as (text word) were used. The following keywords were
entered: asthma* OR wheez* OR, bronchoconstrict* OR
bronchospas* AND pregnancy* OR pregnant OR mater-
nal* in combination with clinical trials OR randomized
controlled trials OR controlled clinical trials. Additional
searches using the Medical Subject Headings (MeSH)
‘asthma’ and ‘pregnancy’ were performed in Medline and
PubMed.
Study selection
One author (EZ) ran the search strategy described above.
All studies identified were imported into an Endnote® li-
brary (version X6, Thomson Reuters). After removal of du-
plicates, the remaining titles and abstracts were reviewed
by EZ to exclude studies that did not meet the inclu-
sion criteria. Full texts of all studies that were considered
relevant on the basis of review of title and abstract were
retrieved, read and assessed independently by two re-
viewers (EZ and JG).
Data collection process and data items
Using an electronic data extraction form [27], one author
(EZ) extracted the data from included studies, which were
verified by a second author (JG). Any disagreements and
uncertainties were identified and resolved in discussion
with an adjudicating third author (KS). Given the clinical
heterogeneity of the studies included, a qualitative assess-
ment of the effects of the intervention was performed,
based on the methodological quality and the study out-
comes. The effects of the intervention were described by
comparing the difference in outcome measures from base-
line to end of the study between the groups. If more than




Figure 1 shows the process of selection of studies for
the systematic review, based on PRISMA guidelines [29].
Overall, 2,387 references published until 9 October 2013
were identified in the preliminary search: Ovid MEDLINE
(n = 636), Ovid EMBASE (n = 779), CINAHL Plus (n = 337),
Ovid PsycINFO (n = 22), IPA (n = 137), Ovid CENTRAL
(n = 143) and PubMed (n = 333). Screening of the refer-
ence lists of published articles resulted in identification of
another 18 articles. After combining the results from each
database and removal of duplicate titles from Endnote®,
1,717 unique studies remained. After further screening,
1,461 were removed due to irrelevant titles or abstracts,
leaving 256 studies for further scrutiny; 247 studies were
excluded after further review. Of the nine full-text articles
obtained, one was a narrative review [30], one had aretrospective design [31], one had a cross-sectional design
[32] and three were based on secondary analysis of other
studies [33-35] leaving only three original studies for the
final review [36-38].
Study characteristics
The characteristics and results of the three studies in-
cluded in the final review are summarized in Table 1.
These studies evaluated the following interventions in
pregnant women: an education program [36], progres-
sive muscle relaxation (PMR) [37] and management of
asthma guided by Fraction of exhaled Nitric Oxide
(FeNO) [38]. Heterogeneity in study design, setting, type
of intervention, follow-up and outcome measures were
found among the three studies. Two studies took place
in the antenatal clinic of one Australian hospital [36,38]
and another [37] in Germany. All three interventions
were conducted in clinics or hospital settings.
Methodological quality
All three studies had methodological limitations. The
education program in the uncontrolled pre- and post-
test design study was delivered by the same personnel
who were involved in outcome assessment and were not
masked (blinded), thus observation/detection bias might
have occurred [36]. Only one of the RCTs reported alloca-
tion concealment [38]. The outcomes of both trials [37,38]
were assessed by masked investigators but only one re-
ported masking of both the participants and personnel
who were involved in the intervention [38]. Sample size
calculation was described for both RCTs, but not in the
pre- and post-test study [36]. Participation and attrition
rates varied across the three studies. Only Powell et al. [38]
gave reasons for participant withdrawal (11 from the trial
group and 6 from the control group). None of the study
protocols were published. One trial was registered with the
Australian and New Zealand Clinical Trial registry [38].
Results of individual studies
Education program
Murphy et al. [36] conducted a study to implement asthma
self-management skills through an education program in
pregnant women with asthma in an antenatal clinic. The
asthma self-management skills assessed were: medication
adherence (inhaled corticosteroid [ICS] users only), know-
ledge about how the reliever and preventer medications
worked and inhaler technique, possession of a written ac-
tion plan, and self-monitoring. The medication adherence
and knowledge were assessed by direct questioning, while
the inhaler technique was demonstrated by the patient.
The study found that maternal and neonatal outcomes
may be improved by asthma self-management education,
which can be delivered in an antenatal clinic by a nurse





Records identified through searching
MEDLINE, EMBASE, CINAHL Plus, PsycINFO, IPA, CENTRAL and 
PubMed
(N = 2,387) 
Additional records identified 
through other sources 
(N = 18) 
Results combined and duplicates removed
(N = 1,717) 
Records included after screening 
of title and abstract
(N= 256) 
Records excluded due to irrelevant titles or 
abstracts
(N =1,461)
Full-text articles assessed for 
eligibility
(N =9)




• Population not meeting inclusion criteria  (N=33) 
• Pharmacological intervention only (N=22)
• Review, editorial, protocol or case report (N=95)
• Study design or study objectives not meeting inclusion criteria 
(N=97)
Full-text articles excluded (N=6)
Reason:
• Narrative Review (N=1) 
• Study design or study objectives not meeting inclusion criteria   
(N=5)
Figure 1 Flow chart of selection process for including studies in the systematic review.
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were associated with asthma education and should be
considered as an important aspect of managing asthma in
pregnant women [36]. There were some limitations of this
study. The time elapsed (~3 months) between the two
visits was identified by the authors as a potential con-
founder, as changes in asthma control could be influenced
by gestation and seasonal changes [36]. Since there was no
comparison group, it remained unclear if the asthma man-
agement skills improved because of the asthma education
provided in the antenatal clinic, as a result of other fac-
tors, or spontaneously [36].
Progressive Muscle Relaxation (PMR)
This trial by Nickel et al. [37] examined the efficacy of
progressive muscle relaxation (PMR) on changes in heart
rate, systolic blood pressure (SBP), lung function and
quality of life in pregnant women with asthma. The
PMR procedures in this study required the participantsto monitor and control their state of muscular tension.
In the first step, the women deliberately applied tension
to certain muscle groups and then released the tension
and focused on how the muscle relaxed during the
process [37]. This study claimed that the PMR interven-
tion was inexpensive and demonstrated a potential bene-
fit in pregnant women with asthma [37]. Inability to
confirm that all the participants followed the instruc-
tions was a limitation acknowledged by the authors [37].
The short term follow-up of the study (8 weeks) may
have contributed to the low drop-out rate [37]. Only im-
mediate effects were measured after an active interven-
tion. Hence it is unknown if PMR intervention would
have had similar effects in the longer term and during
asthma exacerbations [37].
FeNO-based algorithm
Powell et al. [38] carried out a double-blind parallel group
RCT to test whether asthma control in pregnancy would
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(p = 0.037), AQLQ-M
scores were low at the
completion of the study
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pared to an ACQ clinical algorithm in terms of reducing
asthma exacerbations. FeNO helps to identify eosinophilic
airway inflammation and to adjust the dose of ICS. The
FeNO-based algorithm group had a sequential process: (1)
FeNO concentration to adjust the dose of ICS; and (2)
ACQ score to adjust the dose of long acting beta2-agonist.
The clinical algorithm was based on asthma control
assessed with Juniper’s ACQ questionnaire. The data col-
lected included clinical symptoms, ACQ, quality of life
questionnaires (AQLQ-M and SF-12), present treatment
(ICS and β2 agonist), FeNO and spirometry (FEV1, FVC).
This trial showed that the FeNO group had a signifi-
cantly lower rate of asthma exacerbations during preg-
nancy (p = 0.001) and unscheduled doctor visits due to
asthma during pregnancy (p = 0.002) [38]. However the
ACQ scores (symptom-free days) and the AQLQ-M
scores of the two groups were not significantly different
at the end of the study [38]. The mean daily ICS dose
was lower in the FeNO group throughout the study. A
higher median birth weight as well as a reduction in pre-
term deliveries and neonatal hospitalizations was also
found in this group [38].
Discussion
This systematic review evaluated the effectiveness of
non-pharmacological healthcare interventions for im-
proving asthma management in pregnant women. The
three studies included in the review assessed education,
PMR and a FeNO-based algorithm, which were found to
have some positive effects on asthma management in
pregnancy. Firm conclusions however, cannot be drawn
due to the limited number of reported studies, clinical
heterogeneity of the interventions, variations in outcome
measures and limitations in study designs.
Patient education is the cornerstone of asthma man-
agement during pregnancy as it promotes adherence and
in turn, improves asthma control [16]. Gibson et al. [39]
identified four components of an effective asthma educa-
tion program: (1) information about asthma and its
management, (2) self-monitoring of either symptoms or
peak expiratory flow rate, (3) regular medical review for
assessing asthma control, severity and medications, and
(4) a written action plan to guide patient self-management
of asthma exacerbations. Pregnant women with asthma
should have a basic understanding of self-monitoring,
how to use asthma medications correctly, how to manage
worsening asthma and the importance of continued ad-
herence to asthma management plans [16]. Asthma edu-
cation programs and self-management skills have been
proven to be effective in improving health outcomes in
adults with asthma [18]. Both the studies of Murphy et al.
[36] and Powell et al. [38] provided education to pregnant
women on skills and knowledge to manage their asthma,leading to improvement in adherence to medication regi-
mens and asthma action plans.
The 30-min PMR sessions three times a week showed a
greater improvement in lung function compared to sham
training [37]. A systematic review by Huntley et al. [40] con-
cluded that muscular relaxation may improve lung func-
tion. However, there was no evidence for effectiveness on
asthma symptoms in pregnant women with asthma. The
effects of educational interventions and PMR on asthma
at different stages of gestation remain unknown.
The outcomes measured varied among the three stud-
ies. Lung function (e.g. FEV1, PEF) was measured as an
outcome in all of the studies included. All three studies
showed some improvement in FEV1, although only one
study demonstrated a significant improvement in FEV1
as a result of the intervention [37]. During pregnancy,
static lung function remains the same except for a re-
duction in functional residual capacity (FRC), expiratory
reserve volume (ERV) and residual volume (RV) [41]. As
the uterus enlarges, FRC decreases by 10% to 25% of the
previous value due to a 35% to 40% decrease in chest
wall compliance [42]. Normal pregnancy may have no
significant effect on airway function. However in preg-
nant women with asthma, peak flow rate, FEV1 and FVC
may decrease particularly during acute exacerbations
[43]. The study by Schatz et al. [44] observed that it is
important to measure FEV1 regularly during pregnancy,
both as a prognostic factor for perinatal outcomes and
as a measure of asthma control. Monitoring lung func-
tion using spirometry is recommended in the initial
assessment of all pregnant women with asthma and
periodically as needed [45], although lung function is
typically impaired only in severe asthma and during
acute exacerbations. Further studies are needed to con-
firm the efficacy of healthcare interventions in pregnant
women with asthma over different trimesters, as pulmon-
ary function changes throughout pregnancy in asthmatic
women [6,43,46].
Powell et al. [38] reported a significant reduction in
the rate of unscheduled doctor visits for asthma and oral
corticosteroid use in patients receiving FeNO-guided
management. Reduced asthma exacerbations leading to
improvements in both maternal and neonatal outcomes
were also reported [38]. The application of FeNO as a bio-
marker of airway inflammation for the adjustments of ICS
treatment to guide asthma management has been widely
studied, however the results are as yet inconclusive. Several
studies have shown that FeNO-guided asthma management
is no more effective in reducing asthma exacerbations than
current asthma guidelines and conventional pulmonary
tests using spirometry [47-50]. Daily FeNO monitoring has
been shown to be of no added value compared to daily
symptom monitoring. Moreover, FeNO measurements are
not routinely available in most clinical settings [11].
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for monitoring airway inflammation in patients with
asthma. However, there is insufficient evidence to sup-
port more widespread use. Various confounders, including
sex, age, height, measurement technique, exhalation flow
rate, smoking, anti-inflammatory medications and even
what the patient ate for breakfast, may affect FeNO results
[51]. A cross-sectional study by Tamasi et al. [32] showed
that in pregnant women with asthma, FeNO levels are
elevated compared to healthy pregnant women and they
correlate with the level of asthma control. Further studies
comparing FeNO-guided asthma management with sim-
ple implementation of asthma guidelines in conjunction
with conventional lung function monitoring, especially
in pregnant women, are required to confirm any advan-
tage of FeNO monitoring over traditional monitoring/
self-management.
Strengths and weaknesses of this review
This is the first systematic review of the effectiveness of
non-pharmacological healthcare interventions for man-
aging asthma and improving health outcomes in preg-
nant women with asthma. Unpublished studies were not
included in this review. A meta-analysis was not possible
because of the clinical heterogeneity of the data and
study designs.
Practice and research implications
A clinical algorithm for asthma management based on
objective measures and asthma symptoms could poten-
tially reduce asthma exacerbations during pregnancy.
The goals of asthma management in pregnant women
are the same as in non-pregnant patients, which are to
control asthma symptoms, maximize lung function,
minimize medication side effects and prevent asthma ex-
acerbations. These goals need to be considered when de-
signing interventions, in addition to pharmacological
treatment, to improve health outcomes in pregnant
women with asthma. The cost-effectiveness of interven-
tions and satisfaction of patients and health professionals
also need to be assessed before implementation of such
interventions in clinical practice. Further evidence is
needed from well-designed prospective controlled stud-
ies in pregnant women with asthma investigating the ef-
fectiveness of interventions that incorporate patient
education, patient self-management and periodic follow-
up with health professionals.
Conclusions
Our review suggests that non-pharmacological healthcare
interventions including education, self-management, pro-
gressive muscle relaxation and periodic follow-up may
optimize asthma management in pregnancy. Interventions
that enable pregnant women to be monitored regularlyusing objective measures of lung function or asthma
symptoms appear to be more effective in improving health
outcomes during pregnancy.
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